首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1634226

全球光动力治疗市场 - 2024 - 2032

Global Photodynamic Therapy Market - 2024 - 2032

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球光动力治疗市场规模达53亿美元，预计2032年将达到104亿美元，2024-2032年预测期间复合年增长率为8.8%。

光动力疗法(PDT) 是一种尖端的非侵入性治疗方法，使用称为光敏剂的光敏物质，当光敏剂被光激活时，有助于治疗各种医疗状况，包括癌症、皮肤问题和感染。该疗法涉及施用一种被异常或患病细胞吸收的光敏剂。当这些细胞暴露于特定的光波长时，光敏剂被激活，产生活性氧，选择性地损伤目标细胞。

PDT 因其能够提供精确、有针对性的治疗而广受欢迎，与手术和化疗等传统疗法相比，副作用更少。它对于治疗早期或表面癌症特别有效，包括皮肤、肺部、食道和头颈等部位的癌症。除了癌症之外，PDT 在治疗痤疮、老年黄斑部病变 (AMD) 和某些病毒感染等疾病方面也取得了成功。人们对 PDT 日益浓厚的兴趣凸显了其作为现代医学中多功能、微创治疗选择的潜力。

市场动态：

驱动程式和限制

癌症盛行率上升

皮肤癌，特别是基底细胞癌（BCC）和鳞状细胞癌（SCC）等非黑色素瘤类型的盛行率不断上升，预计将显着推动光动力疗法（PDT）市场的发展。皮肤癌病例的增加可归因于长时间暴露在阳光下、晒黑习惯和人口老化等因素。因此，对 PDT 等有效、非侵入性治疗方法的需求不断增加。全球皮肤癌的数量不断增加。例如，根据世界癌症研究基金会的数据，2022 年有超过 331,722 例新发皮肤癌。

PDT 在治疗皮肤癌方面具有几个关键优势。它对于浅表或早期癌症特别有效，这些癌症通常在深入皮肤之前就被发现。 PDT 无需侵入性手术即可精确靶向癌细胞的能力使其成为极具吸引力的选择，特别是对于肿瘤位于敏感或可见区域（例如面部和头皮）的患者。此外，与传统外科手术相比，PDT 具有较低的疤痕和併发症风险，从而增强了其在皮肤癌治疗中的吸引力。

随着皮肤癌发病率持续上升，医疗保健提供者和患者越来越多地考虑 PDT，因为它能够提供局部、有针对性的治疗，且副作用最小。据估计，一段时间内皮肤癌的发生率会增加。预计在预测期内皮肤癌的数量将会增加。例如，GLOBOCAN也预测，2040年印度癌症病例将增加至208万，较2020年增加57.5%。

此外，光敏剂和光传输系统的不断进步预计将进一步提高 PDT 的有效性，扩大其在皮肤癌治疗中的应用。随着早期检测和治疗越来越受到重视，PDT 可能在解决全球皮肤癌病例激增的问题上发挥至关重要的作用。

成本高且供应有限

光动力疗法（PDT）的高成本和有限的可用性预计将对市场的成长构成重大挑战。 PDT 涉及专用设备和光敏剂，购买和维护成本高昂，这使其成为许多医疗保健提供者和患者的昂贵治疗选择。这种高昂的成本可能会限制其可近性，特别是在医疗基础设施欠发达的地区或财政资源有限的低收入国家。此外，由于并非所有医疗机构都具备必要的专业知识或设备，因此需要训练有素的专业人员来有效地实施治疗，这进一步限制了其可用性。

BIOFRONTERA AG
Sun Pharmaceutical Industries Ltd.
Lumibird Medical
Bausch + Lomb.
illumacell
Pinnacle Biologics, Inc.
Zimed Healthcare Inc
MEDlight GmbH
Luzitin, SA
Similar data will be provided for each market player.
再生元製药公司
- 管道产品说明
- 产品关键绩效指标 (KPI)
- 主要活动
- 市场进入时间表
- 产品渗透率
- 销售估算与预测
摩德纳公司
伊马蒂斯公司
BioNTech SE。
菲洛根公司
将为每个市场参与者提供类似的资料。

第 12 章：附录

简介目录

Product Code: PH1036

The global photodynamic therapy market reached US$ 5.3 billion in 2024 and is expected to reach US$ 10.4 billion by 2032, growing at a CAGR of 8.8% during the forecast period 2024-2032.

Photodynamic Therapy (PDT) is a cutting-edge, non-invasive treatment that uses light-sensitive substances called photosensitizers, which, when activated by light, help to treat a variety of medical conditions, including cancer, skin issues, and infections. The therapy involves administering a photosensitizer that is absorbed by abnormal or diseased cells. When these cells are exposed to a specific light wavelength, the photosensitizer is activated, producing reactive oxygen species that selectively damage the targeted cells.

PDT has gained considerable popularity due to its ability to provide precise, targeted treatment with fewer side effects compared to traditional therapies such as surgery and chemotherapy. It is particularly effective for treating early-stage or surface-level cancers, including those in areas like the skin, lungs, esophagus, and head and neck. Beyond cancer, PDT has shown success in managing conditions such as acne, age-related macular degeneration (AMD), and certain viral infections. This growing interest in PDT highlights its potential as a versatile and minimally invasive treatment option in modern medicine.

Market Dynamics: Drivers & Restraints

Rising prevalence of cancer

The growing prevalence of skin cancer, particularly non-melanoma types such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is expected to significantly boost the Photodynamic Therapy (PDT) market. This increase in skin cancer cases can be attributed to factors like extended sun exposure, tanning practices, and the aging population. As a result, the demand for effective and non-invasive treatment methods like PDT is on the rise. There is a growing number of skin cancers around the globe. For instance, according to the World Cancer Research Fund, there were more than 331,722 new cases of skin cancer in 2022.

PDT offers several key benefits in treating skin cancer. It is especially effective for superficial or early-stage cancers, which are often detected before they progress deeper into the skin. PDT's ability to target cancerous cells precisely without requiring invasive surgery makes it a highly attractive option, particularly for patients with tumors located in sensitive or visible areas, such as the face and scalp. Furthermore, PDT is associated with a lower risk of scarring and complications when compared to traditional surgical procedures, enhancing its appeal in skin cancer treatment.

As the incidence of skin cancer continues to rise, healthcare providers and patients are increasingly considering PDT for its ability to provide localized, targeted treatment with minimal side effects. There is an estimated increase in skin cancer over a while. The number of skin cancers is expected to increase in the forecast period. For instance, additionally, GLOBOCAN predicted that cancer cases in India would increase to 2.08 million, accounting for a rise of 57.5 percent in 2040 from 2020.

Additionally, ongoing advancements in photosensitizers and light delivery systems are expected to further improve PDT's effectiveness, broadening its application in skin cancer management. As early detection and treatment become increasingly emphasized, PDT is likely to play a crucial role in addressing the global surge in skin cancer cases.

High Cost and Limited Availability

The high cost and limited availability of Photodynamic Therapy (PDT) are expected to pose significant challenges to the growth of the market. PDT involves specialized equipment and photosensitizers, which can be expensive to acquire and maintain, making it a costly treatment option for many healthcare providers and patients. This high cost can limit its accessibility, especially in regions with less advanced healthcare infrastructure or in lower-income countries where financial resources are constrained. Additionally, the need for trained professionals to administer the therapy effectively further restricts its availability, as not all healthcare facilities have the necessary expertise or equipment.

Segment Analysis

The global photodynamic therapy market is segmented based on product type, application, end-user, and region.

Type:

Laser devices segment is expected to dominate the global photodynamic therapy market share

The Laser Devices segment is poised to dominate the Photodynamic Therapy (PDT) market due to their critical role in the therapy's mechanism of action. Laser devices are essential for activating the photosensitizers used in PDT, delivering the precise wavelengths of light required to treat a variety of conditions, such as skin cancer, acne, and age-related macular degeneration. The ability of lasers to provide highly targeted, accurate, and deep tissue penetration makes them a preferred choice for PDT, as they allow clinicians to focus the treatment on specific areas without causing damage to surrounding healthy tissues.

The segment's growth is also fueled by ongoing technological advancements and product launches. Manufacturers are continuously improving laser devices to enhance their efficiency, precision, and safety. For instance, companies are introducing lasers that offer more adjustable wavelengths, better depth control, and compact designs, making them easier to use in clinical settings. These innovations are expected to further elevate the adoption of laser devices in PDT. For instance, in February 2023, Bausch + Lomb Corp. and biomedical laser firm Modulight Oyj announced that the US Food and Drug Administration has approved their ML6710i photodynamic laser for use with the eye-health company's photodynamic therapy, Visudyne.

Market players are employing strategies that focus on expanding their product portfolios and advancing their technological capabilities. Leading companies in the PDT space are investing in research and development to create next-generation laser devices that can offer more effective treatment options, including improved portability and user-friendly features. Additionally, strategic partnerships and collaborations with healthcare institutions help to increase awareness and availability of laser-based PDT treatments.

As a result of these advancements, laser devices are expected to maintain their dominance in the PDT market, particularly as the demand for non-invasive, precise, and effective treatments grows. With continued product innovation, strategic market moves, and an increasing focus on patient outcomes, the laser devices segment is set to be a key driver of the Photodynamic Therapy market's expansion.

Geographical Analysis

North America is expected to hold a significant position in the global photodynamic therapy market share

North America is expected to dominate the photodynamic therapy (PDT) market due to a combination of factors including advanced healthcare infrastructure, a high prevalence of diseases treatable with PDT (such as skin cancer and age-related macular degeneration), and a strong presence of key market players and research institutions. The region is a leader in the adoption of innovative medical technologies, making it a hub for the development and deployment of PDT treatments.

The major factor driving the region's photodynamic therapy is the rising incidence of skin cancers in the region. With the growing number of skin cancers, the estimated usage and adoption of photodynamic therapy is expected to increase. For instance, according to the American Academy of Dermatology, skin cancer is the most prevalent cancer in the United States. Current estimates suggest that one in five Americans will be diagnosed with skin cancer during their lifetime. Approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. In 2024, it is projected that there will be 200,340 new cases of melanoma, with 99,700 being noninvasive (in situ) and 100,640 being invasive.

Additionally, North America's dominance is the increasing demand for non-invasive, precise, and targeted therapies. PDT offers a compelling alternative to traditional treatments like surgery and chemotherapy, particularly for conditions like superficial cancers, acne, and eye disorders. As awareness of PDT's benefits grows among both patients and healthcare providers, its adoption is expected to increase. Furthermore, North America boasts a well-established healthcare system that facilitates the widespread availability of advanced treatments such as PDT.

In addition, ongoing product launches and innovations from major market players are contributing to the growth of the PDT market in North America. Companies are introducing new PDT devices, particularly laser-based systems, that offer enhanced precision, improved light delivery mechanisms, and better photosensitizers.

Market players in North America are adopting various strategies to strengthen their positions in the PDT market. Key strategies include increasing investment in research and development to create next-generation PDT technologies, expanding product portfolios, and forging partnerships with hospitals, dermatology clinics, and research institutions. Strategic collaborations are helping to expand the reach of PDT treatments, while partnerships with regulatory bodies and clinical researchers enable quicker approvals and clinical trials, thereby speeding up the adoption of new PDT solutions. Thus, the above factors are expected to hold a significant position in the global photodynamic therapy market.

Competitive Landscape

The major global players in the photodynamic therapy market include Galderma Nordic AB, BIOFRONTERA AG, Sun Pharmaceutical Industries Ltd., Lumibird Medical, Bausch + Lomb., illumacell, Pinnacle Biologics, Inc., Zimed Healthcare Inc, MEDlight GmbH and Luzitin, S.A. among others.

Key Developments

In July 2023, ImPact Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for the treatment of patients with locally advanced pancreatic cancer.
In October 2024, Biofrontera Inc. (Nasdaq: BFRI) announced that the database for the treatment phase of the ALA-BCC-CT013 study has been finalized.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Photodynamic Therapy Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising prevalence of cancer
- 4.1.2. Restraints
  - 4.1.2.1. High Cost and Limited Availability
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product Type

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Photosensitizer Drugs*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Porphyrin Derivatives
- 6.2.4. Chlorines
- 6.2.5. Aminolevulinic Acid
- 6.2.6. Others
6.3. Laser Devices

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Oncology*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dermatology
7.4. Ophthalmology
7.5. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cosmetic & Dermatology Clinics
8.4. Cancer Treatment Centers
8.5. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

11.1. Galderma Nordic AB*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
  - 11.1.2.1. Product Description
  - 11.1.2.2. Product Key Performance Indicators (KPIs)
  - 11.1.2.3. Historic and Forecasted Product Sales
  - 11.1.2.4. Product Sales Volume
- 11.1.3. Financial Overview
  - 11.1.3.1. Company Revenue's
  - 11.1.3.2. Geographical Revenue Shares
  - 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
  - 11.1.4.1. Mergers & Acquisitions
  - 11.1.4.2. Key Product Development Activities
  - 11.1.4.3. Regulatory Approvals etc.
- 11.1.5. SWOT Analysis
11.2. BIOFRONTERA AG
11.3. Sun Pharmaceutical Industries Ltd.
11.4. Lumibird Medical
11.5. Bausch + Lomb.
11.6. illumacell
11.7. Pinnacle Biologics, Inc.
11.8. Zimed Healthcare Inc
11.9. MEDlight GmbH
11.10. Luzitin, S.A.
Similar data will be provided for each market player.

Emerging Market Players

11.11. Regeneron Pharmaceuticals Inc.*
- 11.11.1. Pipeline Products Description
- 11.11.2. Product Key Performance Indicators (KPIs)
- 11.11.3. Key Activities
- 11.11.4. Market Entry Timelines
- 11.11.5. Product Penetration Rate
- 11.11.6. Sales Estimation and Projections
11.12. Moderna, Inc.
11.13. Immatics N.V.
11.14. BioNTech SE.
11.15. Philogen S.p.A.
Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE